TICKERNOMICS Sign up
Last Update: 2024-03-28 02:13:07
scPharmaceuticals Inc. ( SCPH ) https://www.scpharmaceuticals.com
4.91USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-45.20%
SCPH
SPY
32.74%
-26.39%
SCPH
SPY
92.93%
SCPH
63.67%
SPY
224.41%
SCPH
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
193.51
177.17
0.30
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-3.69
25.81
5.20
-20.85
0.00
-3.41
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-390.91
71.58
-460.64
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
5.3144
-119.35
-59.92
0.28
Other Earnings and Cash Flow Stats:
scPharmaceuticals Inc. ( SCPH ) Net Income TTM ($MM) is -48.55
scPharmaceuticals Inc. ( SCPH ) Operating Income TTM ($MM) is -45.89
scPharmaceuticals Inc. ( SCPH ) Owners' Earnings Annual ($MM) is 0.00
scPharmaceuticals Inc. ( SCPH ) Current Price to Owners' Earnings ratio is 0.00
scPharmaceuticals Inc. ( SCPH ) EBITDA TTM ($MM) is -40.68
scPharmaceuticals Inc. ( SCPH ) EBITDA Margin is -460.64%
Capital Allocation:
scPharmaceuticals Inc. ( SCPH ) has paid 0.00 dividends per share and bought back -7.610008 million shares in the past 12 months
scPharmaceuticals Inc. ( SCPH ) has increased its debt by 0.876 million USD in the last 12 months
Capital Structure:
scPharmaceuticals Inc. ( SCPH ) Interest-bearing Debt ($MM) as of last quarter is 38
scPharmaceuticals Inc. ( SCPH ) Annual Working Capital Investments ($MM) are -27
scPharmaceuticals Inc. ( SCPH ) Book Value ($MM) as of last quarter is 37
scPharmaceuticals Inc. ( SCPH ) Debt/Capital as of last quarter is 104%
Other Balance Sheet Stats:
scPharmaceuticals Inc. ( SCPH ) has 46 million in cash on hand as of last quarter
scPharmaceuticals Inc. ( SCPH ) has 13 million of liabilities due within 12 months, and long term debt 38 as of last quarter
scPharmaceuticals Inc. ( SCPH ) has 35 common shares outstanding as of last quarter
scPharmaceuticals Inc. ( SCPH ) has 0 million USD of preferred stock value
Academic Scores:
scPharmaceuticals Inc. ( SCPH ) Altman Z-Score is -2.93 as of last quarter
scPharmaceuticals Inc. ( SCPH ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
scPharmaceuticals Inc. ( SCPH ) largest shareholder is Orbimed Advisors, LLC owning 5559528 shares at 27.30 ($MM) value
Orbimed Advisors Llc(an insider) Bought 762380 shares of scPharmaceuticals Inc. ( SCPH ) for the amount of $4002495.00 on 2022-11-25
6.60% of scPharmaceuticals Inc. ( SCPH ) is held by insiders, and 75.58% is held by institutions
scPharmaceuticals Inc. ( SCPH ) went public on 2017-11-17
Other scPharmaceuticals Inc. ( SCPH ) financial metrics:
FCF:-50.01
Unlevered Free Cash Flow:-23.61
EPS:-1.74
Operating Margin:-390.91
Gross Profit Margin:71.58
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-168.03
Beta:0.28
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About scPharmaceuticals Inc. ( SCPH ) :
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.